Quick Answer
SUTRO BIOPHARMA, INC. reported Research And Development Expense of $166.42 million for the year ending 2025.
- SUTRO BIOPHARMA, INC. showed a decrease of -34.0% in Research And Development Expense from 2024 to 2025.
- This data is from SUTRO BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $13.67 million | Q1 2018: $13.08 million | Q2 2018: $13.75 million | Q3 2018: $12.64 million | Q1 2019: $15.18 million | Q2 2019: $16.14 million | Q3 2019: $16.90 million | Q1 2020: $17.62 million | Q2 2020: $17.24 million | Q3 2020: $19.36 million | Q1 2021: $22.56 million | Q2 2021: $25.31 million | Q3 2021: $26.60 million | Q1 2022: $29.99 million | Q2 2022: $32.33 million | Q3 2022: $31.71 million | Q1 2023: $39.40 million | Q2 2023: $41.59 million | Q3 2023: $45.67 million | Q1 2024: $56.88 million | Q2 2024: $62.02 million | Q3 2024: $62.11 million | Q1 2025: $51.60 million | Q2 2025: $38.33 million | Q3 2025: $39.85 million.
- Over the full 10 years of available data (2016 to 2025), SUTRO BIOPHARMA, INC.'s Research And Development Expense has grown by 282.1%.
- Historical annual values: Fiscal year 2025: $166.42 million | Fiscal year 2024: $252.04 million | Fiscal year 2023: $180.43 million | Fiscal year 2022: $137.17 million | Fiscal year 2021: $104.40 million | Fiscal year 2020: $76.96 million | Fiscal year 2019: $65.61 million | Fiscal year 2018: $54.26 million | Fiscal year 2017: $54.64 million | Fiscal year 2016: $43.55 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: